Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single ...
Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a ...
Family of compounds known as 1,2,3,5-tetrazines could have wide application in making new pharmaceuticals, chemical and biological probes, and other products. Chemists at Scripps Research have devised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback